EUVIMEDEUVIMED entdecken
Crossref

Effectiveness of rifaximin in reducing central line‐associated bloodstream infections in pediatric intestinal failure

Emma Johnson iD, Claire Konicek, Nathan Lamb, Joseph Fishbein, Ravi Jhaveri, Valeria Cohran

Journal of Pediatric Gastroenterology and Nutrition · 31.07.2026

DOI: 10.1002/jpn3.70522 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 31.07.2026. Verfasst von Emma Johnson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, American Family Children's Hospital, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Rifaximin, Catheter-Related Infections, Intestinal Failure, Catheterization, Central Venous. Die Arbeit nennt 26 Literaturangaben. Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Due to their dependence on parenteral nutrition, patients with intestinal failure (IF) are at an increased risk of central line‐associated blood stream infections (CLABSIs). Ethanol lock therapies (ELTs) reduce the incidence of CLABSIs, but ELTs work locally in the line and have limited availability in the United States. Rifaximin is a non‐absorbed, enteral antibiotic used to manage small intestinal bacterial overgrowth (SIBO). Our primary objective was to evaluate the effectiveness of rifaximin to prevent CLABSIs in pediatric IF patients.

Methods

This was a retrospective cohort study of patients with IF managed at a single pediatric center between January 2010 and December 2022. Patients in the cohort had at least 1 CLABSI prior to initiation of rifaximin. Data were collected for 12 months pre‐ and post‐rifaximin initiation. CLABSI incidences were compared using Poisson regression with a log transformation.

Results

Thirty‐three patients were included. The observed incidence of CLABSI for all patients in our sample, before and after rifaximin initiation, was 10.2 (8.2, 12.7) and 7.3 (5.8, 9.2) per 1000 central line days, respectively, p = 0.03. Subgroup analysis showed patients who received rifaximin without ELT had signification reduction in CLABSIs, 8.3 versus 3.0 ( p < 0.001). There were no statistically significant differences in the proportion of gram‐positive or gram‐negative bacteria or yeast isolated before and after rifaximin.

Conclusions

Children with IF who were treated with rifaximin experienced fewer CLABSI events, suggesting that rifaximin is a viable option for CLABSI prophylaxis in pediatric IF patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifaximinCatheter-Related InfectionsIntestinal FailureCatheterization, Central VenousAnti-Bacterial AgentsHumansRetrospective StudiesFemaleMaleChild, PreschoolInfantChildParenteral NutritionIncidenceEthanolTreatment Outcome

Stichwörter der Autor:innen

central venous catheterethanol lockparenteral nutritionsepsissmall intestinal bacterial overgrowth

Substanzen

RifaximinAnti-Bacterial AgentsEthanol

Autor:innen und Institutionen

  • Department of Pharmacy, American Family Children's Hospital, Madison, Wisconsin, USA.
  • Division of Pharmacy, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
  • Division of Infectious Diseases, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
  • Division of Gastroenterology, Hepatology, and Nutrition, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.

ORCID-Profile: Emma Johnson

Förderung

  • None

Zitieren

APA

Johnson, E., Konicek, C., Lamb, N., Fishbein, J., Jhaveri, R., & Cohran, V. (2026). Effectiveness of rifaximin in reducing central line‐associated bloodstream infections in pediatric intestinal failure. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70522

Vancouver

Johnson E, Konicek C, Lamb N, Fishbein J, Jhaveri R, Cohran V. Effectiveness of rifaximin in reducing central line‐associated bloodstream infections in pediatric intestinal failure. Journal of Pediatric Gastroenterology and Nutrition. 2026. doi:10.1002/jpn3.70522

BibTeX
@article{Johnson2026,
  author = {Johnson, Emma and Konicek, Claire and Lamb, Nathan and Fishbein, Joseph and Jhaveri, Ravi and Cohran, Valeria},
  title = {Effectiveness of rifaximin in reducing central line‐associated bloodstream infections in pediatric intestinal failure},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2026},
  doi = {10.1002/jpn3.70522}
}
Kostenlos starten →